Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting
The data we and our research colleagues are presenting at ASCO demonstrate the clear and growing contribution of liquid biopsy in transforming cancer care and helping to improve patient outcomes.
Featured presentations demonstrate the use of Guardant's portfolio of blood tests, real-world data and AI to identify genomic and epigenomic biomarkers that can inform treatment decisions across a variety of solid tumor types. Studies also highlight new capabilities of the Guardant360 Liquid test to identify molecular tumor type in carcinomas of unknown primary and confirm the absence of actionable biomarkers, both enabled by the Guardant Infinity™ smart liquid biopsy platform, Presentation highlights include:
Abstract LBA4 plenary session demonstrating the use of the Guardant360® CDx test in detecting emergent ESR1 mutations during first-line endocrine-based therapy and ahead of disease progression in patients with HR+/HER2- advanced breast cancer in the Phase 3 SERENA-6 trial
Abstract 3504 oral session evaluating tissue-free epigenomic-based molecular residual disease (MRD) detection using Guardant Reveal™ in stage III colon cancer patients after surgery and prior to adjuvant therapy. This study showed a robust prognostic utility of Reveal to identify patients with poorer disease-free and overall survival in a large clinical trial cohort of over 2,000 patients with a median follow-up of 6.1 years.
Abstract 3584 providing analytic and clinical validation of an algorithm to predict the absence of actionable mutations in ctDNA-negative colorectal and non-small cell lung cancer samples, utilizing genomic and epigenomic profiling with the Guardant360 Liquid test.
Abstract 3073 demonstrating application of an epigenomic-based classifier to identify tumor type on liquid biopsy in cancer of unknown primary origin. Study provides validation data for the new molecular tumor type feature of Guardant360 Liquid utilizing DNA methylation signatures across thousands of cancer-specific differentially methylated regions for 14 cancer types.
'The data we and our research colleagues are presenting at ASCO demonstrate the clear and growing contribution of liquid biopsy in transforming cancer care and helping to improve patient outcomes,' said Helmy Eltoukhy, Guardant Health chairman and co-CEO. 'The SERENA-6 study in particular highlights how we are pushing the boundaries of what can be done with liquid biopsy in characterizing disease and potential drug efficacy, providing insights that could potentially change clinical practice.'
The full abstracts for Guardant Health and a list of all abstracts being presented at ASCO 2025 can be found on the ASCO website.
For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook or visit ASCO booth #25077.
Guardant Health and collaborator presentations at ASCO
Saturday, May 31, 9:00 am – 12:00 pm CT
3584/253
Analytic and clinical validation of a negative prediction algorithm for actionable mutations utilizing genomic and epigenomic profiling in cfDNA
Guardant360 Liquid
4200/490
Circulating tumor DNA-based genomic profiling and real-world outcomes in cancer of unknown primary (CUP)
Guardant360 Liquid
GuardantINFORM
Expand
Saturday, May 31, 1:30 pm – 4:30 pm CT
8528/8
Genomic and circulating tumor DNA landscape in young-onset non-small cell lung cancer
Guardant360 Liquid
8642/122
Use of targeted therapy, healthcare costs, and survival with large panel testing, narrow testing, or no molecular testing in patients with metastatic non-small cell lung cancer (mNSCLC)
Guardant360 Liquid
Guardant360 CDx
10550/275
Validation of a plasma cell-free DNA methylation-based multi-cancer detection test
Shield MCD
Expand
Sunday, June 1, 2:41 pm – 2:53 pm CT (Plenary Session, Hall B1, Live Stream)
LBA4
Oral Clinical Science Symposium: Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial
Guardant360 CDx
Expand
Sunday, June 1, 4:30 pm – 6:00 pm CT (Arie Crown Theater, Live Stream)
1012
Oral Clinical Science Symposium: Assessment of ctDNA somatic homologous recombination deficiency (HRD) in triple-negative breast cancer (TNBC) from SWOG S1416 trial
Guardant OMNI
Expand
Monday, June 2, 9:00 am – 12:00 pm CT
1052/31
Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) measured by Guardant Reveal in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with long-term disease control on first-line trastuzumab-pertuzumab
Guardant Reveal
1075/54
Use of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and CDK4/6 inhibitor (CDK4/6i) therapy (tx) and to analyze intrinsic vs acquired endocrine resistance
Guardant360 Liquid
5052/251
Evaluating the prognostic utility of cell-free (cf)DNA tumor fraction (TF) in metastatic castration-resistant prostate cancer (mCRPC)
Guardant360 Liquid
5053/252
Real world outcomes for patients with metastatic castration resistant prostate cancer (mCRPC) and AR T878A alterations treated with enzalutamide
GuardantINFORM
5077/276
Real-world prevalence of homologous recombination repair alterations (HRRa) and poly (ADP-ribose) polymerase inhibitor (PARPi) use/outcomes in patients (pts) with metastatic prostate cancer (mPC) by race and ethnicity
GuardantINFORM
5086/285
Association between epigenomic biomarkers and baseline clinical characteristics in patients with mCRPC treated with rucaparib in TRITON2
Guardant Infinity
Expand
Monday, June 2, 1:30 pm – 4:30 pm CT
3073/388
Application of an epigenomic-based classifier to identify cancer signal of origin on liquid biopsy in cancer of unknown primary cases
Guardant360 Liquid
3074/389
HRD status prediction in patients with advanced breast, prostate, ovarian and pancreatic cancers in a liquid biopsy assay
Guardant360 Liquid
Expand
5512
Oral Abstract Session: Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer: Longitudinal changes in circulating tumor DNA
Guardant Infinity
Expand
Online Abstracts
e20536
Accelerating treatment decisions with liquid biopsy NGS in non-small cell lung cancer
Guardant360 Liquid
e13084
Targeted agents for the treatment of hormone receptor–-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer (HR+/HER2- MBC) with co-alterations in ESR1 and AKT pathway: A retrospective analysis
Guardant360 Liquid
Expand
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Eos Energy Enterprises Inc (EOSE) Q2 2025 Earnings Call Highlights: Record Revenue Growth Amid ...
Revenue: $15.2 million in Q2, a 46% increase from Q1. Shipments: 122% increase quarter over quarter. Gross Loss: $31 million, with a 32-point margin improvement from the prior quarter. Operating Expenses: $32.9 million, with $5.4 million in one-time items. Net Loss: $222.9 million, including non-cash fair value adjustments. Adjusted EBITDA Loss: $51.6 million, showing a 75% margin increase. Backlog: $672 million, representing 2.6 gigawatt hours of storage. Commercial Pipeline: $18.8 billion, representing 77 gigawatt hours, a 37% year-over-year increase. Cash Position: Ended the quarter with $183 million in total cash. Production Tax Credits: Generated $14.3 million in credits, collected $6.3 million in cash. Warning! GuruFocus has detected 9 Warning Signs with EOSE. Release Date: July 31, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Eos Energy Enterprises Inc (NASDAQ:EOSE) reported a record revenue increase of 122% quarter over quarter, demonstrating strong operational performance. The company has successfully scaled its operations, achieving higher efficiency and throughput with the same processes and labor. Eos Energy Enterprises Inc (NASDAQ:EOSE) has secured significant financial backing, raising $336 million in the second quarter, which strengthens its cash position and supports manufacturing expansion. The company is benefiting from the One Big Beautiful Bill Act, which preserves production tax credits and supports its American-made energy storage systems. Eos Energy Enterprises Inc (NASDAQ:EOSE) has a growing commercial pipeline valued at $18.8 billion, with a notable increase in standalone storage projects and data center opportunities. Negative Points Eos Energy Enterprises Inc (NASDAQ:EOSE) reported a net loss of $222.9 million for the quarter, influenced by non-cash fair value adjustments tied to stock price changes. The company experienced a gross loss of $31 million, although there was a margin improvement from the prior quarter. There are uncertainties in customer timelines and financing, which could impact the realization of second-half sales. The company faces challenges in ramping up its second production line, with timelines dependent on customer demand and capital allocation. Eos Energy Enterprises Inc (NASDAQ:EOSE) is still negotiating the location for its Factory 2.0, which could delay expansion plans. Q & A Highlights Q: When is line 2 expected to be fully operational, and will this include the subassembly line? A: Joe Mastrangelo, CEO: We are forecasting line 2 to come online in the first half of next year. It will share some of the subassembly capacity with line 1, and eventually, we will add more subassembly capacity as we ramp up. Line 2 will be designed for total throughput efficiency, incorporating lessons learned from line 1 to improve quality, reliability, and throughput. Q: What is the current status of finalizing the site for factory 2.0? A: Joe Mastrangelo, CEO: We are still in negotiations with multiple states and are not discussing specifics publicly. The response has been tremendous, and we are working to secure the right facility with a long-term partnership in mind. We will update once we have news to share. Q: How have customer timelines or urgency shifted post the Big Beautiful Bill (BBB) law, and are there any major barriers still preventing deal commitments? A: Nathan Kroeker, CCO and Interim CFO: The finalization of the BBB law has removed uncertainty, leading some customers to accelerate projects to meet new timelines. We are seeing increased interest from customers looking to switch to non-lithium technology due to restrictions. While these deals take time due to multiple stakeholders, we are confident in moving them forward quickly. Q: How is Eos building a partner ecosystem to support broader adoption? A: Nathan Kroeker, CCO and Interim CFO: We are focusing on developing strategic relationships with integrators and equipment suppliers, especially for complex project sites. This involves identifying preferred technologies and partners, conducting simulations, and ensuring flawless project execution. This strategy is as crucial for commissioning and field projects as it is for sales channels. Q: Can you add some color to how you bridge the revenue for the second half of the year? A: Joe Mastrangelo, CEO: We have been doubling production quarter over quarter for the last nine months, and we plan to continue this trend. The automation of our subassemblies is starting to produce and feed the line, which will help us achieve our revenue guidance. We are focused on maintaining this doubling effect to meet our targets. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Allegro Microsystems Inc (ALGM) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
Revenue: $203 million, a 5% sequential increase and 22% year-over-year growth. Gross Margin: 48.2%, an increase of 260 basis points sequentially. Operating Margin: 11.1% of sales, up from 9% in Q4 and 6% a year ago. Non-GAAP EPS: $0.09, above the midpoint of guidance. Adjusted EBITDA: 16.4% of sales. Automotive Sales Growth: 3% sequential increase, 13% year-over-year growth. E-mobility Sales Growth: 16% sequential increase, 31% year-over-year growth. Industrial and Other Sales Growth: 11% sequential increase, 50% year-over-year growth. Cash Flow from Operations: $62 million. Free Cash Flow: $51 million or 25% of sales. Debt Repayment: Voluntary repayment of $35 million, reducing debt balance to $310 million. Net Debt: Reduced to $181 million from $224 million at the end of Q4. Inventory Days: 141 days, down from 148 in Q4. Warning! GuruFocus has detected 5 Warning Signs with ALGM. Release Date: July 31, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Allegro Microsystems Inc (NASDAQ:ALGM) reported strong first quarter results with sales of $203 million and a gross margin of 48.2%, both above the high end of guidance ranges. The company saw significant growth in e-mobility sales, particularly in current sensors for xEV applications, with a 16% sequential increase and a 31% year-over-year increase. Allegro Microsystems Inc (NASDAQ:ALGM) achieved more than 75% of first quarter design wins in strategic focus areas, including e-mobility, data center, robotics and automation, clean energy, and medical applications. The company released innovative new products, such as an ASIL C current sensor and a FortiGate BYOL motor driver IC, enhancing its leadership in EV inverters and data center cooling solutions. Allegro Microsystems Inc (NASDAQ:ALGM) continues to optimize manufacturing processes, resulting in cost reductions and improved gross margins, with a focus on relentless innovation and performance leadership. Negative Points Operating expenses were $75 million, which was $3 million above the outlook due to increased variable compensation and R&D spending. The company faces foreign exchange headwinds from a weakening US dollar, impacting gross margins. There is ongoing competition in the Chinese market, particularly at the lower end, which could impact Allegro Microsystems Inc (NASDAQ:ALGM)'s market share. The company is not yet shipping to true end demand, indicating potential inventory imbalances in the distribution channel. Allegro Microsystems Inc (NASDAQ:ALGM) is still in the process of transitioning its products to a China for China supply chain, which requires significant effort and time. Q & A Highlights Q: Can you discuss the forward demand picture and the impact of potential tariff pull-ins versus continued recovery? A: Michael Doogue, President and CEO, explained that Allegro is seeing positive trends such as strong bookings and growing backlog. While tariffs create uncertainty, discussions with customers indicate potential future component shortages due to real demand, particularly in industrial and automotive sectors. Derek D'Antilio, CFO, added that the impact of tariffs on Allegro is currently immaterial, with no direct impact on their shipments. Q: What helped drive the upside in gross margin, and how do you see the drivers of gross margin moving forward? A: Derek D'Antilio, CFO, noted that Q1 gross margin exceeded expectations due to better-than-expected revenue and cost benefits from supplier negotiations. Looking forward, they expect continued benefits from cost reductions and a favorable mix, with a projected gross margin of 48% to 50% in Q2. Q: How do you view the automotive demand recovery, and what are your expectations for automotive sales growth? A: Michael Doogue, President and CEO, mentioned that S&P revised their automotive production forecast upwards, indicating a flat vehicle production landscape. Allegro is seeing increased demand from automotive customers, with signs pointing to a recovery in the sector. Q: Can you provide more details on the industrial exposure, particularly in clean energy and data center sectors? A: Michael Doogue, President and CEO, explained that while clean energy is a part of their industrial focus, they are seeing strong growth in data center and robotics sectors. The industrial business has experienced four consecutive quarters of growth, with data center leading the recent uptick. Q: What are the future drivers for e-mobility, and how do you see the timing of new products impacting growth? A: Michael Doogue, President and CEO, highlighted that e-mobility growth is driven by increasing dollar content in steering and braking systems, as well as current sensors in EVs. Allegro's isolated gate drivers are expected to drive significant growth, particularly in the EV and data center markets. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Business Wire
14 minutes ago
- Business Wire
Trividia Health UK Announces Launch of TRUEplus 5-Bevel Pen Needles in UK
LONDON & FT. LAUDERDALE, Fla.--(BUSINESS WIRE)--Trividia Health UK Limited, announced today that the TRUEplus 5-Bevel Pen Needles are now available in the United Kingdom. This new 5-bevel insulin pen needle line gives healthcare providers the ability to provide a variety of different needle gauges and sizes at a low cost to their patients with diabetes. The TRUEplus 5-Bevel Pen Needles are designed for maximum comfort, delivering high quality, safety and ease-of-use and are available in multiple different needle sizes to meet the needs of people with diabetes (31 Gauge 5mm, 6mm, 8mm, and 32 Gauge 4mm). TRUEplus 5-Bevel pen needles feature a unique needle design to help improve comfort of painful insulin injections and increases patient acceptance.* As of now Trividia's TRUEplus 5-bevel pen needles are the lowest priced 5-bevel pen needles to be offered on prescription. Currently many patients are prescribed older, less comfortable, 3-bevel product designs at the same price or higher than the TRUEplus 5-bevel pen needles. 'Providing accessibility to a range of products for patients to confidently manage their diabetes is a priority for us at Trividia Health. Having the TRUEplus 5-Bevel Pen Needles as registered products in the UK allows healthcare providers the option to provide patients with high-quality, low-cost pen needles to manage their diabetes,' said Jonathan Chapman, President and CEO of Trividia Health. The TRUEplus 5-Bevel Pen Needles are widely available throughout the United States and are sold under the TRUEplus brand name as well as the brand names of the nation's premier retail pharmacies. Expansion of availability into the UK market represents the first time TRUEplus 5-Bevel Pen Needles have been available outside of the United States. About Trividia Health UK Limited Trividia Health UK Limited is a subsidiary of Trividia Health, Inc. Trividia Health, Inc. is a global consumer health and wellness company based in Fort Lauderdale, Florida U.S.A and a leading developer, manufacturer and marketer of advanced performance products for people with diabetes, including a broad portfolio of blood glucose monitoring supplies and technologies. With products sold under TRUE and store brand labels, the company is the partner and supplier of affordable, high-quality blood glucose monitoring and health and wellness solutions for the world's leading retail pharmacies, distributors and mail service providers. For more information, please visit: *Reference on file.
